Alto Neuroscience (NYSE:ANRO) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Alto Neuroscience (NYSE:ANRO) issued its quarterly earnings data on Tuesday. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05, Zacks reports.

Alto Neuroscience Price Performance

ANRO traded down $0.06 during trading on Thursday, hitting $4.47. 163,351 shares of the company traded hands, compared to its average volume of 373,630. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.85 and a current ratio of 19.85. The stock’s 50-day simple moving average is $10.02 and its two-hundred day simple moving average is $11.46. Alto Neuroscience has a 1 year low of $3.61 and a 1 year high of $24.00.

Analyst Ratings Changes

Several analysts have issued reports on the company. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Robert W. Baird decreased their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Wedbush lowered shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $29.00 to $4.00 in a research report on Wednesday, October 23rd. Stifel Nicolaus reduced their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, RODMAN&RENSHAW downgraded shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.